Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Brausi M., Oddens J., Sylvester R., Bono A., van de Beek C., van Andel G., ...More

EUROPEAN UROLOGY, vol.65, no.1, pp.69-76, 2014 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 65 Issue: 1
  • Publication Date: 2014
  • Doi Number: 10.1016/j.eururo.2013.07.021
  • Journal Name: EUROPEAN UROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.69-76
  • Keywords: Urothelial carcinoma, Non-muscle-invasive bladder cancer, Maintenance BCG, Dose reduction, Side effects, MITOMYCIN-C, EUROPEAN ORGANIZATION, PRACTICE RECOMMENDATIONS, UROTHELIAL CARCINOMA, FORMAL METAANALYSIS, III TRIAL, 27 MG, PROGRESSION, TOXICITY, TUMORS
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No


Background: Although bacillus Calmette-Guerin (BCG) has proven highly effective in non-muscle-invasive bladder cancer (NMIBC), but it can cause severe local and systemic side effects.